Wednesday Aug 20
Study Results from J. Lee and Colleagues in the Area of Breast Cancer ...
Editor at Clinical Trials Week -- Research findings on Oncology are discussed in a new report.
Wednesday Aug 20
Glenmark Enters Oncology With the Discovery and Initiation of IND...
Glenmark Pharmaceuticals S.A. , a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India , announces the discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 1302, a HER2xCD3 bispecific antibody.
Tue Aug 19, 2014
Good neighbors are good for your heart
A drug used to treat a rare type of bone marrow cancer restores hair in patients with an autoimmune disease that causes hair loss, a new study found.
The Negative Impact Of Pfizer's Mergers And Budget Cuts On Cancer R&D
"And then, I don't know if Mikael Dolsten is on the call, but just a question on business development, analyzing, outlicensing activity.
Thu Aug 14, 2014
Blanco Goode Trust
A UB study that will explore why a breast cancer treatment causes cardiotoxicity in some patients has received significant support to move forward.
Popular southern fare may harm your kidneys
The types of food that many Southerners seem to prefer -- fried foods, sweet drinks and processed meals -- may be deadly for people with kidney disease, a new study suggests.
Wed Aug 13, 2014
Reports Outline Immunoglobulins Findings from M. Woisetschlager and...
They are small fully functional antibody alternatives that bind antigen and elicit effector functions such as antibody-dependent cytotoxicity and complement-dependent cytotoxicity."
Mon Aug 11, 2014
Merrimack Pharmaceuticals Inc. Announces Initiation Of HERMIONE, A...
Merrimack Pharmaceuticals, Inc. today announced the initiation of a global, open-label, randomized Phase 2 trial of MM-302, a HER2-targeted nanoliposomal encapsulation of doxorubicin, in combination with trastuzumab in patients with HER2-positive locally advanced or metastatic breast cancer.
Medical News Today
Kadcyla: NICE disappointed by manufacturer's decision
The National Institute for Health and Care Excellence is very disappointed that Roche, the manufacturer of Kadcyla has decided not to offer its new treatment at a price that would enable it to be available for routine use in the NHS.
Sat Aug 09, 2014
San Diego NewsCape
Can chemotherapy side effects increase the risk of heart disease?
Chemotherapy side effects may increase the risk of heart disease, including weakening of the heart muscle and rhythm disturbances .
Fri Aug 08, 2014
Brits balk at high price of Roche cancer drug
The British National Institute for Health and Clinical Excellence decides that Roche's breast cancer drug Kadcyla is too expensive for routine use by the National Health Service despite the company's offering of a discount.
Wed Aug 06, 2014
Reports on Chemotherapy Findings from National Taiwan University...
Editor at Biotech Week -- Current study results on Drugs and Therapies have been published.
The Future of Coverage and Payment for Personalized Medicine Diagnostics
The past decade has seen incredible progress for the scope and impact of personalized medicine.
Tue Aug 05, 2014
Four costly medicines for treating cancer, hepatitis C now covered by free health scheme
CANCER AND HEPATITIS C patients will receive better coverage under the universal healthcare scheme as the board of the National Health Security Office has approved an additional four expensive medicines for it.
Thu Jul 31, 2014
No TV or obesity, but ancient people still had heart disease
A new report finds that by 2010, one in every 10 visits Americans made to their doctor's office involved diabetes, with the greatest rise among those aged 25 to 44. A new report finds that by 2010, one in every 10 visits Americans made to their doctor's office involved diabetes, with the greatest rise among those aged 25 to 44. Although the vast ... (more)
Mon Jul 28, 2014
The Guardian of Genome and Targeted Therapies in Non Diabetic, HER2...
Rome, Central Italy, June 2014. The study entitled "p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab" has been recently judged suitable for publication in Oncotarget and will be soon available online.